Partners and collaborators in our scientific discovery

Biotech collaborations, pharma collaborations and scientific collaborations: Discover the possibilities of working with Glycotope and contribute to revolutionize the future of biotechnology with us.

Glycotope’s success in advancing antibody research is supported by valuable research collaborations as well as pharma collaborations, with leading academic and industry experts. We are proud to present our projects with renown partners around the world, driving innovation and breakthroughs in cancer therapy.

Our strategic collaborations amplify our efforts by combining our expertise with global leaders to expand the therapeutic application of our antibodies. Due to their unmatched tumor specificity, they can be developed into multiple mechanisms of action. Together with our partners, we strive to combine our antibodies with complementary technologies to fully exploit their capabilities and enable novel therapies.

Our partnerships are critical to accelerating the development and reflect our commitment to open ways for new methods of treatments. The foundation is a shared understanding of our values and vision. An open and cooperative approach is particularly important to us.

We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology. Please use the contact form to discuss a collaboration in the development of antibodies for cancer immunotherapy.

Start a collaboration

Examples for our partners and collaborations

Industry Partners

Evotec: Based on a licensing agreement signed in 2023, Glycotope and Evotec combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec – An important pharma collaboration for us.

Daiichi Sankyo: Based on a worldwide licensing agreement signed in 2018, Daiichi Sankyo, a renowned pharmaceutical partner, develops an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody GT-00A.

LegoChem Biosciences: LCB and Glycotope have signed a Research Collaboration and License Agreement to develop an antibody drug conjugate (ADC) by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational tumor targeting antibodies. Upon successful completion of a feasibility study, LCB has the right to exercise an option for worldwide exclusive rights to develop and commercialize the selected antibody as ADC.

Academic Partners and research collaborations

Medizinische Hochschule Hannover: The MHH and Glycotope have joined forces to research the suitability of carbohydrate antigens for CAR-T development.

Charité Comprehensive Cancer Center: The scientific partnership between Glycotope and the Charité Comprehensive Cancer Center has existed for many years. During this time, a wide variety of projects have been carried out jointly to advance cancer treatment.

Max Delbrück Center: Glycotope and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Become a partner